吉祥坊登录

Recently， Shanghai MicroPort Endovascular MedTech Co., Ltd.( Endovastec™) was listed as “2018 Shanghai Science and Technology Little Giant Enterprise”. In future,  the selected companies will gain funding from city or district (county) governments based on the companies' independent innovation plans.Before then, MicroPort® Endovascular was successfully Selected as “2016 Shanghai Science and Technology Little Giant Enterprise(for Cultivation)”, and passed the project acceptance inspection in 2018.

As a local technology enterprise, EndovastecTM was founded in 2012, which is committed to develop, manufacture, and sale of state-of-the-art technologies and products in healthcare business, focusing on providing solutions for aortic and peripheral diseases, always be product-and-technology-oriented, continues to develop and innovate products with independent intellectual property rights, owns 127 patents. In recent years, EndovastecTM has been selected as Shanghai High-tech Enterprise, Shanghai Specialized, Sophisticated, Distinctive, Innovative SMEs, Shanghai Patent Affairs Pilot Enterprise and Pudong New Area Enterprise Institution etc. EndovastecTM gained the Second Prize of" Key Technology Development and Large-scale Industrialization of Aortic Stent Graft Products" in2017 and the project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases" won the First Prize of Shanghai Science and Technology Progress Award in 2016. In particular, EndovastecTM shows the outstanding performance in product innovation. Since the government opened the special review and approval procedure for innovative medical devices, 5 products which are self-developed by EndovastecTMhave entered this “Green Path”. Among them, Castor Branched Aortic Stent-Graft System (The world's first product approved by regulators for the treatment of aortic arch disease) has gained the registration certificate and started the production and sales.

Miao Zhenghua, the president of EndovastecTM, said:“EndovastecTM is able to be selected as “2018 Shanghai Science and Technology Little Giant Enterprise” it shows the government's recognition on the innovative capabilities and core technology R&D of EndovastecTM, which will definitely fuels their motivation for innovation. In the future, EndovastecTM, will further enhance its innovation capabilities, increase the input in R&D, to drive its developments,to benefit more patients."

Under the direction of Science and Technology Commission of Shanghai Municipality and Shanghai Municipal Commission of Economy and Informatization, the Science and Technology Little Giant Project aims to provide support to unlisted high-tech SMEs (small- and medium-sized enterprises) registered in Shanghai so as to foster the strategic and emerging industries such as information technology, smarter healthcare and bio-tech industries. The candidate has to meet strict requirements regarding the percentage of its R&D headcount, its R&D expenses in recent three fiscal years, its major business revenue in the previous year, the average growth rate of its revenue or net profit in the previous three years, management team and finical regulations. It will be further assessed through oral defense and online review before eventually be selected as "2016 Shanghai Science and Technology Little Giant Enterprise."